Get started
Author

Daiki Murata

Observed names: D. Murata, DAIKI MURATA, Daiki MURATA
Observed institutions: Kurume University, Hiroshima University, Kyoto University, Kurume University Hospital, Hiroshima City Asa Citizens Hospital, National Hospital Organization, Kure Medical Center, Kindai University
ORCID: 0000-0002-4295-5046
Observed ORCID: 0000-0002-4295-5046
OpenAlex ID: A5117594180
High programmed cell death 1 ligand–1 expression: association with CD8+ T-cell infiltration and poor prognosis in human medulloblastoma
2017 · Daiki Murata, Yohei Mineharu, et al. · Journal of neurosurgery · 49
PDF
PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes
2018 · Bin Liu, Yoshiki Arakawa, et al. · PLoS ONE · 33
PDF
Prognostic effect of cachexia in patients with non‐small cell lung cancer receiving immune checkpoint inhibitors
2023 · Norikazu Matsuo, Koichi Azuma, et al. · Thoracic Cancer · 26
PDF
Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors
2023 · Daiki Murata, Koichi Azuma, et al. · Cancer Medicine · 20
A case of cytokine release syndrome accompanied with COVID ‐19 infection during treatment with immune checkpoint inhibitors for non‐small cell lung cancer
2022 · Daiki Murata, Koichi Azuma, et al. · Thoracic Cancer · 19
PDF
Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor‐induced interstitial lung disease in patients with non‐small cell lung cancer
2022 · Daiki Murata, Koichi Azuma, et al. · Thoracic Cancer · 14
PDF
CD44 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma
2021 · YOHEI SEKINO, KENSHIRO TAKEMOTO, et al. · Anticancer Research · 14
PDF
High mobility group A1 expression shows negative correlation with recurrence time in patients with glioblastoma multiforme
2015 · Bin Liu, Bo Pang, et al. · Pathology - Research and Practice · 14
Survival and soluble immune mediators of immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer
2023 · Daiki Murata, Koichi Azuma, et al. · Lung Cancer · 13
Retrospective Analysis of Bevacizumab in Combination With Ifosfamide, Carboplatin, and Etoposide in Patients With Second Recurrence of Glioblastoma
2013 · Yoshiki ARAKAWA, Takashi MIZOWAKI, et al. · Neurologia medico-chirurgica · 13
PDF
Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy
2024 · Daiki Murata, Koichi Azuma, et al. · Cancer Immunology Immunotherapy · 9
PDF
Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinoma
2022 · Jun Teishima, Daiki Murata, et al. · Current Urology · 9
P53 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma
2021 · YOHEI SEKINO, KENSHIRO TAKEMOTO, et al. · Anticancer Research · 9
PDF
C‐reactive protein can be used to predict the therapeutic effects of nivolumab in patients with metastatic renal cell carcinoma
2019 · Jun Teishima, Daiki Murata, et al. · International Journal of Urology · 8
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non–Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study
2024 · Naoya Nishioka, Tae Hata, et al. · Cancer Research and Treatment · 7
PDF
A Cluster of Paragonimiasis with Delayed Diagnosis Due to Difficulty Distinguishing Symptoms from Post-COVID-19 Respiratory Symptoms: A Report of Five Cases
2023 · Jun Sasaki, Masanobu Matsuoka, et al. · Medicina · 6
PDF
A Rare Case of Diffuse Bilateral Minute Pulmonary Meningothelial-like Nodules Increasing over the Short Term and Resembling Metastatic Lung Cancer
2022 · Daiki Murata, Yoshiaki Zaizen, et al. · Internal Medicine · 6
PDF
Impact of immune-related adverse events on clinical outcomes in patients with advanced non-small cell lung cancer with low PD-L1 expression, focusing on pneumonitis: a multicenter retrospective study in Japan
2025 · Shiho Goda, Tadaaki Yamada, et al. · Translational Lung Cancer Research · 4
Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
2025 · Tae Hata, Tadaaki Yamada, et al. · Cancer Research Communications · 3
PDF
Impact of stratifin/14-3-3σ on survival and interstitial lung disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors
2025 · Daiki Murata, Koichi Azuma, et al. · Cancer Immunology Immunotherapy · 2
PDF
Improved prognosis for elderly patients with metastatic renal cell carcinoma in the era of targeted therapy
2020 · Jun Teishima, Daiki Murata, et al. · Molecular and Clinical Oncology · 2
PDF
[Infected Pelvic Lymphocele after Robot-Assisted Radical Prostatectomy].
2019 · Daiki Murata, Koji Mita, et al. · PubMed · 2
PDF
Biomarker study on pneumonitis in durvalumab maintenance therapy after chemoradiotherapy for stage III non-small cell lung cancer
2025 · Ryo Yano, Takaaki Tokito, et al. · BMC Cancer · 1
Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective study
2025 · Daiki Murata, Koichi Azuma, et al. · Lung Cancer · 1
Dual Targets, Two Paths: Amivantamab: A Promising Treatment for NSCLC With Exon 14 Skipping Mutations of MET
2025 · Daiki Murata, Hidetoshi Hayashi · Journal of Thoracic Oncology · 1
PDF
Works count: 69
Citation count: 291
H-index: 10
I10-index: 10
Year
Topic
Type